Mumbai, Feb. 28 -- Under this agreement, the company will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent.

The CDMO agreement will be executed through its in-house R&D and manufacturing capacities at Savli Vadodara, Gujarat.

Anil Jain, joint managing director, Bajaj Healthcare said: "I am thrilled to share this strategic collaboration which underscores Bajaj Healthcare Ltd.'s commitment to innovation, excellence, and meeting the evolving needs of the pharmaceutical industry.

By harnessing our expertise and state-of-the-art infrastructure, we are poised to...